InnoCan Pharma Corporation INNPF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -25.06% | -17.07% | -7.65% | -20.90% | -18.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.06% | -17.07% | -7.65% | -20.90% | -18.95% |
| Cost of Revenue | -40.69% | -15.57% | -43.75% | -25.33% | 25.54% |
| Gross Profit | -23.02% | -17.22% | 0.48% | -20.41% | -22.54% |
| SG&A Expenses | -5.99% | 0.71% | 3.72% | -0.79% | -20.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.89% | -0.77% | -6.49% | -2.80% | -18.52% |
| Operating Income | -228.28% | -260.74% | -0.33% | -446.02% | -25.56% |
| Income Before Tax | -96.33% | -2,590.91% | 53,000.00% | -303.99% | -107.60% |
| Income Tax Expenses | -131.07% | -75.57% | -613.73% | -47.37% | -56.90% |
| Earnings from Continuing Operations | 52.38% | -286.90% | 3,964.58% | -681.69% | -132.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 142.18% | 75.64% | 312.12% | 48.61% | 55.57% |
| Net Income | 94.24% | -67.01% | 1,850.00% | -571.38% | -275.07% |
| EBIT | -228.28% | -260.74% | -0.33% | -446.02% | -25.56% |
| EBITDA | -224.20% | -255.91% | 0.33% | -434.35% | -25.28% |
| EPS Basic | 94.21% | -65.85% | 1,825.97% | -546.94% | -268.21% |
| Normalized Basic EPS | 100.31% | -804.95% | 1,277.24% | -690.38% | -198.91% |
| EPS Diluted | 94.21% | -65.85% | 1,825.97% | -546.94% | -268.21% |
| Normalized Diluted EPS | 100.31% | -804.95% | 1,277.24% | -690.38% | -198.91% |
| Average Basic Shares Outstanding | 0.06% | 0.72% | 1.47% | 3.83% | 4.12% |
| Average Diluted Shares Outstanding | 0.06% | 0.72% | 1.47% | 3.83% | 4.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |